Ocular Therapeutix (OCUL) Interest Expenses (2013 - 2026)

Ocular Therapeutix has reported Interest Expenses for 14 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 6.94% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 7.06% YoY), and the FY2025 full-year result was $11.8 million, down 12.83% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.8 million, down from $2.8 million in the prior quarter.
• The five-year high for Interest Expenses was $4.2 million in Q4 2023, with the low at $1.7 million in Q1 2022.
• Average Interest Expenses over 5 years is $2.7 million, with a median of $3.0 million recorded in 2025.
• Year-over-year, Interest Expenses surged 129.13% in 2024 and decreased 26.34% in 2025.
• Tracing OCUL's Interest Expenses over 5 years: stood at $1.8 million in 2022, then jumped by 124.74% to $4.2 million in 2023, then declined by 25.17% to $3.1 million in 2024, then declined by 8.82% to $2.8 million in 2025, then declined by 1.94% to $2.8 million in 2026.
• The last three Interest Expenses figures came in at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.

Peer Comparison